SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

Camzyos

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved; post-market Phase 3 long-term safety extension completed
Time to market
Already approved and on the market, FDA approval recorded April 28, 2022 (per local FDA catalyst records)
Why 3/10
Camzyos is already approved (FDA approval recorded 2022-04-28) and commercialized with NO hard, dated regulatory catalyst in the next ~12 months, the only pending item is a Phase 3 long-term safety extension (NCT03723655) that completed 2026-01-16 with results not yet posted and no announced readout date, so as one Growth-Portfolio drug inside a mega-cap it scores 3.
Actionable Insight NEUTRAL

Watch for two things: (1) BMY posting MAVA-LTE long-term safety data for Camzyos (safety of the myosin-inhibitor class is the key risk) and quarterly Growth Portfolio/Camzyos sales commentary; and (2) the bigger HCM binary this year is actually the competitor's, Cytokinetics' aficamten (MYQORZO) has a PDUFA on 2026-11-14, which will set the competitive narrative for Camzyos. Do not expect a Camzyos-specific binary to move BMY much on its own.

Price Chart

Loading chart...

Executive Summary

Camzyos (mavacamten) is Bristol Myers Squibb's first-in-class treatment for hypertrophic cardiomyopathy, approved by the FDA on April 28, 2022 per local FDA catalyst records, an already-commercialized drug with no pending regulatory decision. The only open item is a 314-patient Phase 3 long-term safety extension (NCT03723655) completed January 2026 with results not yet posted. It faces direct competition from Cytokinetics' aficamten (MYQORZO), already approved in the US/EU/China for obstructive HCM, which posted positive Phase 3 data in non-obstructive HCM and has a Nov 14, 2026 PDUFA for a further label expansion.

How It Works

Camzyos (mavacamten) is an oral small-molecule drug used to treat hypertrophic cardiomyopathy, a genetic condition, per the trial records, in which the heart muscle thickens and contracts too forcefully and can block blood flow out of the heart. It is a cardiac myosin inhibitor: it slows the heart muscle's over-active contraction by dampening the 'motor' protein that powers each heartbeat. (Note: external web sources were unreachable this session, so this mechanism description relies on the drug's established public profile plus the local trial/FDA records.)

Trial Status

The 314-patient Phase 3 long-term safety extension study (NCT03723655, MAVA-LTE) in adults who completed the MAVERICK-HCM or EXPLORER-HCM trials was completed 2026-01-16 (actual primary completion); local records show results not yet posted (hasResults=false), with no announced readout date.

The Two-Sided Case

▲ Bull Case4
Already approved (FDA approval recorded 2022-04-28) and commercialized, the defining regulatory binary has passed, removing approval risk for the obstructive-HCM indication.
Fits within a strong company backdrop: BMY's Q2 2026 earnings 8-K (per local LLM analysis) beat consensus, non-GAAP EPS of $2.04 vs $1.60 estimate and revenue of $13.0B vs $11.74B, and FY2026 revenue guidance was raised to $49.0B-$50.0B, with Camzyos part of the Growth Portfolio.
BMY screens inexpensive on local quant data (forward P/E 9.88, quant composite score 45) and short interest is modest (2.20% of estimated shares outstanding, 4.24 days-to-cover at the 2026-07-15 settlement), leaving room for a positive surprise.
First-in-class position in hypertrophic cardiomyopathy, with an ongoing 314-patient long-term safety extension (NCT03723655) that completed enrollment/follow-up, results pending.
▼ Bear Case4
Direct competition is ahead on data: Cytokinetics' aficamten (MYQORZO) is already approved for obstructive HCM in the US, EU and China (per local press records), posted positive Phase 3 ACACIA-HCM results in non-obstructive HCM on 2026-05-05 (dual primary endpoints met), and has a PDUFA of 2026-11-14 for the MAPLE-HCM oHCM expansion, a faster-moving franchise that could pressure Camzyos' share.
No near-term hard catalyst for Camzyos itself: the long-term safety extension completed 2026-01-16 but results are not posted and no readout date is set; safety of the myosin-inhibitor class (heart-failure risk) is the ongoing watch item.
Camzyos is a small piece of a mega-cap, so single-drug news moves BMY little, the stock was actually DOWN -0.71% (1-day) around the 2022-04-28 approval date per local catalyst-outcome records.
Analyst positioning is balanced-to-cautious: BMY consensus is 'hold' (recommendation mean 2.56; 19 hold vs 14 buy/strong-buy vs 2 sell) with mean price target $64.91 vs a $65.31 last price, implied upside roughly -0.5%.

Upcoming Catalysts

  • Posting of MAVA-LTE (NCT03723655) long-term safety results, no date announced, results 'pending'
  • Competitor read-through: aficamten sNDA PDUFA 2026-11-14 (Cytokinetics, CYTK), sets the competitive narrative for the HCM class
  • BMY quarterly earnings (next after the 2026-07-30 Q2 release) for Camzyos / Growth Portfolio sales commentary
  • Any label-expansion or new-trial announcements for mavacamten from BMY

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov